Trending
Revolutionary Shows Promise 4
Revolutionary Shows Promise 3
Revolutionary Shows Promise 1
Revolutionary aids Treatment Shows Promise
Revolutionary Cancer Treatment Shows Promise
FDA Expands Approval of Vonvendi for von Willebrand Disease, Including Pediatric Use
Child Depression Fluctuations may trigger Parent Depression not vice versa: JAMA
Indoor Air Quality and Diet Found to Regulate Inflammation in Childhood: Study Finds
How Smoking Fuels Pancreatic Cancer Growth and Worsens Outcomes: Study Finds Out
Follow Us:
November 03, 2025

Get In Touch

Boehringer Ingelheim Told to File Separate Phase IV Trial Plan for Empagliflozin Pharma News

Boehringer Ingelheim Told to File Separate Phase IV Trial Plan for Empagliflozin

  • 01 November 2025
  • 1 day ago

CDSCO Panel Rejects Pure and Cure's Empagliflozin-Based FDC, Flags Risk of UTI, Genital Mycosis Pharma News

CDSCO Panel Rejects Pure and Cure's Empagliflozin-Based FDC, Flags Risk of UTI, Genital Mycosis

  • 20 October 2025
  • 1 week ago

Empagliflozin exhibits Safety and Renal Effects in Cirrhosis With T2DM: Study Diabetes and Endocrinology

Empagliflozin exhibits Safety and Renal Effects in Cirrhosis With T2DM: Study

  • 26 September 2025
  • 1 month ago

NPPA Fixes Retail Prices of 9 Formulations Including Dapagliflozin, Sitagliptin, Aceclofenac FDCs, Details Pharma News

NPPA Fixes Retail Prices of 9 Formulations Including Dapagliflozin, Sitagliptin, Aceclofenac FDCs, Details

  • 17 September 2025
  • 1 month ago

Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil Pharma News

Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil

  • 15 September 2025
  • 1 month ago

Dapagliflozin and Empagliflozin Shows Comparable Effectiveness in Type 2 Diabetes: Study Diabetes and Endocrinology

Dapagliflozin and Empagliflozin Shows Comparable Effectiveness in Type 2 Diabetes: Study

  • 10 September 2025
  • 1 month ago

Glyceraldehyde Derivatives Inspired By Empagliflozin Potential Anti-Heart Failure Agents Independent Of Glucose-Lowering Effects: Study Diabetes and Endocrinology

Glyceraldehyde Derivatives Inspired By Empagliflozin Potential Anti-Heart Failure Agents Independent Of Glucose-Lowering Effects: Study

  • 22 July 2025
  • 3 months ago

Recent News

Himachal notifies Resident doctor policy 2025

  • 02 November, 2025

Pfizer files lawsuit against Metsera, its Director...

  • 02 November, 2025

Health Ministry achieves 3 Guinness World Records...

  • 02 November, 2025

Roche gets CE mark for Elecsys Dengue Ag test to d...

  • 02 November, 2025

Aadhaar authentication voluntary for NBE exams, cl...

  • 02 November, 2025

Daily Newsletter

Get all the top stories from Blogs to keep track.